- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06255665
A Study of JNJ-79032421 Targeting Mesothelin for Advanced Stage Solid Tumors
April 23, 2024 updated by: Janssen Research & Development, LLC
A Phase 1 Study of JNJ-79032421, a T-cell Redirecting Agent Targeting Mesothelin for Advanced Stage Solid Tumors
The purpose of this study is to determine recommended phase 2 dose(s) (RP2Ds) of JNJ-79032421 and to determine the safety and tolerability of JNJ-79032421 at the RP2D(s).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
120
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Study Contact
- Phone Number: 844-434-4210
- Email: Participate-In-This-Study@its.jnj.com
Study Locations
-
-
-
Barcelona, Spain, 08035
- Recruiting
- Hosp. Univ. Vall D Hebron
-
Madrid, Spain, 28040
- Recruiting
- Hosp. Univ. Fund. Jimenez Diaz
-
Madrid, Spain, 28050
- Recruiting
- Hosp. Univ. Hm Sanchinarro
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Histologically or cytologically confirmed diagnosis of one of the following unresectable/locally advanced or metastatic solid tumors: a) Ovarian cancer includes high grade serous epithelial ovary, fallopian tube, or primary peritoneal cancer. Participants must have progressed after at least 2 prior lines of systemic therapy and have either, i) platinum-refractory disease (ie, persistent disease following completion of platinum-based primary chemotherapy); or ii) platinum-resistant recurrent disease; b) Primary pleural or peritoneal mesothelioma. Sarcomatoid and well differentiated papillary histologies are not allowed. Participants must have progressed after at least 1 prior line of systemic therapy; c) Pancreatic ductal adenocarcinoma. Other histologies and mixed histologies are not allowed. Participants must have progressed after at least 1 prior line of systemic therapy.
- Measurable or evaluable disease: a) Part 1: Measurable or evaluable disease; b) Part 2: At least one measurable lesion per RECIST v1.1. Participants with mesothelioma must have disease measurable per mRECIST v1.1.
- Can have a prior or concurrent second malignancy (other than the disease under study) whose natural history or treatment is unlikely to interfere with any study endpoints of safety or the efficacy of the study treatment(s)
- Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1.
- Selected participants in the pharmacokinetic and pharmacodynamic (PK/PD) cohorts (Part 1) as well as selected participants in Part 2 must agree to undergo mandatory tumor biopsies.
Exclusion Criteria:
- History of known central nervous system (CNS) or leptomeningeal involvement.
- Left ventricular ejection fraction on screening echocardiogram below normal institutional limits.
- History of talc pleurodesis for pleural effusion within 3 months of starting study treatment.
- Concurrent empyema of the lung pleural space requiring antibiotics or chest tube or evidence of resultant fistula formation.
- History of hyperthermic intraperitoneal chemotherapy (HIPEC) within 6 months of starting study treatment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part 1 (Dose Escalation): JNJ-79032421
In Part 1 (Dose escalation), participants will receive JNJ-79032421.
The dose will be escalated sequentially until the recommended phase 2 dose (RP2D) regimen(s) have been identified.
|
JNJ-79032421 will be administered.
JNJ-79032421 will be administered at RP2D regimen.
|
Experimental: Part 2 (Dose Expansion): JNJ-79032421
In Part 2 (Dose expansion), participants will receive JNJ-79032421 at the RP2D regimen(s) determined in Part 1.
|
JNJ-79032421 will be administered.
JNJ-79032421 will be administered at RP2D regimen.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 1: Number of Participants with Dose Limiting Toxicity (DLTs)
Time Frame: Up to first 21 days after first dose
|
The DLTs are adverse events including certain high grade non-hematologic or hematologic toxicities, or toxicities meeting other specific criteria.
|
Up to first 21 days after first dose
|
Part 1 and Part 2: Number of Participants with Adverse Events (AEs) by Severity
Time Frame: Up to 3 years
|
An AE is any untoward medical occurrence in a clinical study participant administered an investigational or non-investigational product and it does not necessarily have a causal relationship with the investigational product.
Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0 with the exception of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome events (ICANS), which will be graded by American Society for Transplantation and Cellular Therapy (ASTCT) guidelines.
Severity scale ranges from grade 1 (mild) to grade 5 (death).
Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening and Grade 5= death related to adverse event.
|
Up to 3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 1 and Part 2: Serum Concentration of JNJ-79032421
Time Frame: Up to 3 years
|
Serum concentration of JNJ-79032421 will be reported.
|
Up to 3 years
|
Part 1 and Part 2: Maximum Observed Analyte Concentration (Cmax) of JNJ-79032421
Time Frame: Up to 3 years
|
Cmax is defined as maximum observed analyte concentration of JNJ-79032421.
|
Up to 3 years
|
Part 1 and Part 2: Time to Reach Maximum Observed Analyte Concentration (Tmax) of JNJ-79032421
Time Frame: Up to 3 years
|
Tmax is defined as the time to reach maximum observed analyte concentration of JNJ-79032421.
|
Up to 3 years
|
Part 1 and Part 2: Area Under the Curve from Time t1 to Time t2 (AUC[t1-t2]) of JNJ-79032421
Time Frame: Up to 3 years
|
AUC(t1-t2) is defined as area under the analyte concentration for a specific time interval defined by t1 and t2 (AUC[t1-t2]) of JNJ-79032421.
|
Up to 3 years
|
Part 1 and Part 2: Number of Participants with Presence of Anti-JNJ-79032421 Antibodies
Time Frame: Up to 3 years
|
The maximum titers of antibodies to JNJ-79032421 will be summarized for participants positive with antibodies to JNJ-79032421.
|
Up to 3 years
|
Part 1 and Part 2: Objective Response Rate (ORR)
Time Frame: Up to 3 years
|
ORR is defined as the percentage of participants with a best response of complete response or partial response according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1), and revised mRECIST for assessment of malignant pleural mesothelioma.
|
Up to 3 years
|
Part 1 and Part 2: Duration of Response (DOR)
Time Frame: Up to 3 years
|
DOR is defined as the duration from the date of initial documentation of a response (PR or CR) to the date of first documented evidence of relapse or death according to RECIST v. 1.1, and revised mRECIST for malignant pleural mesothelioma.
|
Up to 3 years
|
Part 1 and Part 2: Cancer Antigen (CA) 125 Response Rate for Ovarian Cancer Only
Time Frame: Up to 3 years
|
CA 125 response rate is defined as the proportion of participants with ovarian cancer who achieved a partial response or complete response according to the Gynecologic Cancer Intergroup (GCIG) response criteria for CA 125.
A CA 125 response is defined as at least 50 percentage (%) reduction in CA 125 levels from a pretreatment sample which must be confirmed and maintained for at least 28 days.
|
Up to 3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 9, 2024
Primary Completion (Estimated)
February 10, 2027
Study Completion (Estimated)
February 10, 2027
Study Registration Dates
First Submitted
February 5, 2024
First Submitted That Met QC Criteria
February 5, 2024
First Posted (Actual)
February 13, 2024
Study Record Updates
Last Update Posted (Actual)
April 24, 2024
Last Update Submitted That Met QC Criteria
April 23, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR109341
- 2023-504896-26-00 (Registry Identifier: EUCT number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical-trials/transparency.
As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Stage Solid Tumors
-
Tianjin Hemay Oncology Pharmaceutical Co., LtdRecruitingPatients With Advanced Stage Solid TumorsChina
-
MedPacto, Inc.National OncoVentureCompletedAdvanced Stage Solid TumorsUnited States
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
-
NantCell, Inc.CompletedQUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
-
Glendale Adventist Medical Center d/b/a Adventist...Caris Life SciencesRecruitingStage III Solid Tumors | Stage IV Solid TumorsUnited States
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
Glendale Adventist Medical Center d/b/a Adventist...GUARDANT HEALTHRecruitingStage III Solid Tumors | Stage IV Solid TumorsUnited States
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Solid Tumors, Neoplasms, Advanced SolidHungary
Clinical Trials on JNJ-79032421
-
Janssen Research & Development, LLCRecruitingLymphoma, Non-HodgkinDenmark, Israel, Spain, Australia
-
Janssen-Cilag International NVCompleted
-
Janssen Research & Development, LLCCompleted
-
Janssen Research & Development, LLCCompleted
-
Janssen Research & Development, LLCCompleted
-
Janssen Research & Development, LLCCompleted
-
Janssen Research & Development, LLCCompleted
-
Janssen Research & Development, LLCCompleted
-
Janssen-Cilag International NVCompleted
-
Janssen Research & Development, LLCActive, not recruitingLymphoma, Non-Hodgkin | Chronic Lymphocytic LeukemiaUnited States, Israel, Korea, Republic of, Netherlands, Belgium, Spain, Australia, Poland, France, Georgia, Moldova, Republic of, Ukraine